The Conversation (0)
BELLUS Health released its financial results for the third quarter of 2017.
BELLUS Health (TSX:BLU) released its financial results for the third quarter of 2017.
As quoted in the press release:
“The data presented in two preclinical models during our Key Opinion Leader event demonstrated the differentiated profile of BLU-5937 and highlighted its potential to drive comparable anti-cough effect to the leading P2X3 antagonist, but with a substantially improved side effect profile” said Roberto Bellini, President and CEO of BELLUS Health. “During the quarter we made significant strides towards moving BLU-5937 into human clinical studies and continue to expect filing a Clinical Trial Application, to support starting a Phase 1 study, in the second quarter of 2018.”
Q3 2017 Highlights
BLU-5937
On September 18, 2017, the Company announced that BLU-5937 showed a significant reduction in cough and no taste disturbance in two separate preclinical models. In the guinea pig cough model, BLU-5937 showed comparable efficacy to the current leading P2X3 antagonist, Merck & Co’s Gefapixant (also named AF-219 or MK-7264). In the rat taste model, BLU-5937 did not inhibit taste; however, consistent with clinical trial data previously presented by Merck & Co, Gefapixant led to significant taste disturbance.
The Company is currently performing preclinical studies on BLU-5937 to complete its package for submission of a Clinical Trial Application (CTA), expected in the second quarter of 2018. The Company plans to initiate a Phase 1 clinical study in the third quarter of 2018.
Click here to read the full press release.
Source: www.newswire.ca
